New Treatment Strategies in the Management of Mycosis FungoidesCutaneous Lymphoma Programs H Lee Moffitt Cancer Center and Research Institute George Washington University

Fax 212-712-8495 Email [email protected] Web www.cancercare.org The content of this booklet is independent, non-promotional and free of commercial influence and bias. The

Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphomaTechnology appraisal guidance Published: 24 April 2019 www.nice.org.uk/guidance/ta577 © NICE

Cutaneous T-Cell Lymphomas (CTCLs) Types, Treatment and Research Most people have never heard of cutaneous T-cell lymphomas (CTCLs). Compared to lung and breast cancers,

Slide 1Lyn McDivitt Duncan, M.D. Professor of Pathology, Harvard Medical School Director, Massachusetts General Hospital Dermatopathology Unit HARVARD MEDICAL SCHOOL Lymphoma

NCCN Guidelines for Patients Mycosis Fungoides/Sézary SyndromeMycosis Fungoides/Sézary Syndrome It's easy to get lost in the cancer world 9Step-by-step

doi:10.1016/S0140-6736(08)60420-1www.thelancet.com Vol 371 March 15, 2008 945 Mycosis fungoides and Sézary syndrome Sam T Hwang, John E Janik, Elaine S Jaff e, Wyndham

Mycosis fungoides and Sézary syndrome: a population-wide study on prevalence and health care use in Finland in 1998–2016RESEARCH ARTICLE Open Access Mycosis

Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, riskstratification, and managementWilcox Ryan (Orcid ID: 0000-0002-6420-0760) Mycosis Fungoides and

Mogamulizumab for previously treated mycosis fungoides and Sézary syndromeTechnology appraisal guidance Published: 15 December 2021 www.nice.org.uk/guidance/ta754